Ascend Research

CRWV earnings

Analysis, not advice

A Technology company with about $9.9B of trailing revenue, more than double the prior year's, but it is spending heavily to build capacity: capex of roughly $27.6B against operating cash flow of $7.2B left free cash flow near -$20B, funded with about $66B of debt on only $4B of equity. The stock jumped about 25% in a day to $60.77, and the business has just tipped from a small operating profit to a roughly breakeven operating loss.

This print
10 Nov 2026reported — not yet graded
cons -1.27 EPS / 3.54B rev
What the desk tested

Explicit conditions that would change the desk’s view — grading follows the transcript.

Bull condition (test): The print would need to show backlog becoming accepted, revenue-producing capacity alongside improving GAAP economics and a funded cash-spending path; this is a proposed pathway…
Bear condition (test): Test each approved condition below on its stated basis; missing evidence must remain unresolved rather than become an assumed pass.
From the desk's pre-read · 10 Nov 2026

CRWV is scheduled to report on 2026-11-10; FMP consensus is cons -1.27 EPS / 3.54B rev, with the earnings basis and consensus snapshot date unavailable.

+1 more — the full pre-read is on the desksign up free
The desk's graded verdict

The 10 Nov 2026 print is not graded yet. It lands here once the desk has published against the transcript.

Bull case

Revenue is growing about 130% year over year with a ~67% gross margin, so if the capacity build is met with sustained demand, operating leverage could return quickly.

Bear case

Free cash flow is deeply negative, debt is about 16x equity, and operating margin slipped from positive to negative, leaving little cushion if growth slows or financing gets tighter.

This page shows one print. The desk has published work on 1 earlier print of CRWV.

Educational analysis, not a personalised recommendation. See all covered names on the earnings calendar · part of our public track record.